Literature DB >> 29166426

Rhinology Future Debates, an EUFOREA Report.

W J Fokkens1, C Bachert2, M Bernal-Sprekelsen3, J Bousquet4, M Djandji5, A Dorenbaum6, D Hakimi-Mehr7, S Hendry8, C Hopkins9, A Leunig10, L Mannent11, D Mucha12, M Onerci13, B Pugin14, S Toppila-Salmi15, P Rowe16, S F Seys14, S Stimson17, A Strzembosz18, P W Hellings19.   

Abstract

The first Rhinology Future Debates was held in Brussels in December 2016, organized by EUFOREA (European Forum for Research and Education in Allergy and Airways diseases). The purpose of these debates is to bring novel developments in the field of Rhinology to the attention of the medical, paramedical and patient community, in a highly credible and balanced context. For the first time in Rhinology, a peer to peer scientific exchange with key experts in the field of rhinology and key medical colleagues from leading industries let to a brainstorming and discussion event on a number of hot issues in Rhinology. Novel developments are presented by key experts from industry and/or key thought leaders in Rhinology, and then followed by a lively debate on the potential positioning of new developments in care pathways, the strengths and weaknesses of the novel development(s), and comparisons with existing and/or competing products, devices, and/or molecules. As all debates are recorded and distributed on-line with limited editing (www.rhinology-future.com), EUFOREA aims at maximizing the education of the target groups on novel developments, allowing a critical appraisal of the future and a more rapid implementation of promising novel tools, techniques and/or molecules in clinical practise in Europe. The next Rhinology Future debate will be held in Brussels in December 2017.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29166426     DOI: 10.4193/Rhin17.221

Source DB:  PubMed          Journal:  Rhinology        ISSN: 0300-0729            Impact factor:   3.681


  3 in total

Review 1.  Precision Medicine in Chronic Rhinosinusitis with Nasal Polyps.

Authors:  Klementina Avdeeva; Wytske Fokkens
Journal:  Curr Allergy Asthma Rep       Date:  2018-03-24       Impact factor: 4.806

Review 2.  Stepwise approach towards adoption of allergen immunotherapy for allergic rhinitis and asthma patients in daily practice in Belgium: a BelSACI-Abeforcal-EUFOREA statement.

Authors:  P W Hellings; B Pugin; G Mariën; C Bachert; C Breynaert; D M Bullens; J L Ceuppens; G Clement; T Cox; D Ebo; P Gevaert; S Halewyck; V Hox; K Ladha; R Jacobs; P Rombaux; R Schrijvers; K Speleman; X Van der Brempt; L Van Gerven; O Vanderveken; B Verhaeghe; K Vierstraete; S Vlaminck; J-B Watelet; J Bousquet; S F Seys
Journal:  Clin Transl Allergy       Date:  2019-02-04       Impact factor: 5.871

Review 3.  EUFOREA consensus on biologics for CRSwNP with or without asthma.

Authors:  Wytske J Fokkens; Valerie Lund; Claus Bachert; Joaquim Mullol; Leif Bjermer; Jean Bousquet; Giorgio W Canonica; Lauren Deneyer; Martin Desrosiers; Zuzana Diamant; Joseph Han; Enrico Heffler; Claire Hopkins; Roger Jankowski; Guy Joos; Andrew Knill; Jivianne Lee; Stella E Lee; Gert Mariën; Benoit Pugin; Brent Senior; Sven F Seys; Peter W Hellings
Journal:  Allergy       Date:  2019-07-15       Impact factor: 13.146

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.